このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

肺結核治療のための新規レジメンの無作為化適応的用量範囲非盲検試験 (RAD-TB)

肺結核治療のための新規レジメンの第 2 相無作為適応的用量範囲非盲検試験

A5409/RAD-TB is an adaptive Phase 2 randomized, controlled, open-label, dose-ranging, platform protocol to evaluate the safety and efficacy of multidrug regimens for the treatment of adults with drug-susceptible pulmonary tuberculosis (TB).

A5409 hypothesizes that novel regimens for the treatment of pulmonary tuberculosis will result in superior early efficacy, as determined by longitudinal mycobacteria growth indicator tube (MGIT) liquid culture time to positivity (TTP) measurements over the first 6 weeks of treatment, and will have acceptable safety and tolerability over 8 weeks of treatment relative to standard of care [(SOC) isoniazid/rifampicin/pyrazinamide/ethambutol (HRZE)].

The study will run for 52 weeks, inclusive of 26 weeks of TB treatment comprised of 8 weeks of study treatment (experimental or SOC, based on treatment arm assignment) followed by 18 weeks of SOC continuation phase treatment with 346 participants in Wave 1: 49-50 participants in each experimental treatment arm and 98-100 participants in the SOC treatment arm.

調査の概要

研究の種類

介入

入学 (推定)

341

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Pune、インド、411001
        • 31441, Byramjee Jeejeebhoy Government Medical College (BJGMC) CRS
      • Kampala、ウガンダ
        • 12401, Joint Clinical Research Centre (JCRC)/Kampala CRS
      • Kampala、ウガンダ
        • 30293 MU-JHU Research Collaboration (MUJHU CARE LTD) CRS
      • Eldoret、ケニア、30100
        • 12601, Moi University Clinical Research Center (MUCRC) CRS
      • Kericho、ケニア、20200
        • 12501, Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS
      • Harare、ジンバブエ
        • 30313, Milton Park CRS
      • Bangkok、タイ、10700
        • 5115, Siriraj Hospital, Mahidol University NICHD CRS
      • Chiang Mai、タイ、50200
        • 31784, Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS
      • Pathum Wan、タイ、10330
        • 31802, Thai Red Cross AIDS Research Centre (TRC-ARC) CRS
    • Changwat Chiang Rai
      • Chiang Rai、Changwat Chiang Rai、タイ、57000
        • 5116 Chiangrai Prachanukroh Hospital NICHD CRS
      • Port-au-Prince、ハイチ、6110
        • 30022, Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS
      • Port-au-Prince、ハイチ、6110
        • 31730, GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS
      • Cavite、フィリピン、4118
        • 31981, TB HIV Innovations and Clinical Research Foundation Corp.
      • Porto Alegre、ブラジル、91350
        • 12201, Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS
      • Rio de Janeiro、ブラジル、21040
        • 12101, Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS
      • Hanoi、ベトナム、100000
        • 32483 National Lung Hospital CRS
      • Lima、ペルー、15063
        • 11301, Barranco CRS
      • Lima、ペルー
        • 11302, San Miguel CRS San Miguel
    • Lima Province
      • Lima、Lima Province、ペルー、15234
        • 31985, Socios En Salud Sucursal Perú CRS
      • Gaborone、ボツワナ、0000
        • 12701, Gaborone CRS
      • Blantyre、マラウイ
        • 30301, Blantyre CRS
      • Lilongwe、マラウイ、A-104
        • 12001, Malawi CRS
      • Mexico City、メキシコ、14080
        • 32078, Nutrición-Mexico CRS
      • Cape Town、南アフリカ、6850
        • 31793, South African Tuberculosis Vaccine Initiative (SATVI) CRS
      • Cape Town、南アフリカ、7700
        • 31792, University of Cape Town Lung Institute (UCTLI) CRS
      • Durban、南アフリカ、4001
        • 31422, CAPRISA eThekwini CRS
      • Durban、南アフリカ、4052
        • 11201, Durban International CRS
      • Johannesburg、南アフリカ、1862
        • 12301, Soweto ACTG CRS
      • Johannesburg、南アフリカ、2193
        • 11101, Wits Helen Joseph (WITS HJH) CRS
      • Rustenburg、南アフリカ
        • 31684, Rustenburg CRS

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Pulmonary TB (among individuals either without history of prior TB treatment or with history of TB treatment completed more than 2 years prior to study entry), identified within 7 days prior to study entry by at least one sputum specimen positive for Mtb by Xpert. Semiquantitative Mtb results of "medium" or "high" from Xpert MTB/RIF Ultra are required.

  2. Pulmonary TB with documented INH susceptibility (by Line Probe Assay (LPA) or Xpert MTB/XDR or other validated molecular test) and with documented RIF susceptibility (by LPA or Xpert MTB/RIF or Xpert MTB/RIF Ultra or other validated molecular test) within 7 days prior to study entry.

  3. Documentation of HIV-1 infection status, as below:

    Presence or absence of HIV-1 infection, as documented by:

    • Any licensed rapid HIV test or HIV-1 enzyme or chemiluminescence immunoassay (E/CIA) test kit, any time prior to study entry. AND for a positive result confirmation by one of the following:
    • A second antibody test from different manufacturers or based on different principles and epitopes (combination antigen-antibody-based rapid tests may be used), or
    • HIV-1 antigen, or
    • Plasma HIV-1 RNA viral load, or
    • A licensed Western blot
  4. For individuals with HIV: CD4+ cell count ≥100 cells/mm3 based on testing performed within 30 days prior to study entry.

  5. For individuals with HIV: Currently being treated with dolutegravir-based antiretroviral therapy (ART), or plan to initiate dolutegravir-based ART at or before study week 8.

  6. Individuals age ≥18 years.

  7. The following laboratory values obtained within 7 days prior to study entry at any network-approved non-U.S. laboratory that operates in accordance with Good Clinical Laboratory Practices (GCLP) and participates in appropriate external quality assurance programs:

    • Serum or plasma alanine aminotransferase (ALT) ≤3 times the upper limit of normal (ULN)
    • Serum or plasma total bilirubin ≤2 times ULN
    • Serum or plasma creatinine ≤2 times ULN
    • Serum or plasma potassium ≥3.5 mEq/L
    • Serum or plasma magnesium ≥1.0 mEq/L (≥0.500 mmol/L)
    • Absolute neutrophil count (ANC) ≥1500/mm^3
    • Hemoglobin ≥9.0 g/dL
    • Platelet count ≥100,000/mm^3
    • Negative for, hepatitis B surface antigen (HBsAg)
    • Negative for hepatitis C virus (HCV) antibody (or if HCV antibody positive, must have a negative HCV PCR)
  8. For female study candidates who are of reproductive potential, negative pregnancy test (urine HCG or serum β-HCG) within 3 days (72 hours) prior to entry by any network-approved non-U.S. laboratory or clinic that operates in accordance with GCLP and participates in appropriate external quality assurance programs.

    Females who are of reproductive potential and who participate in sexual activity that could lead to pregnancy must agree to use at least two of the following forms of birth control while receiving TB study medications and for 12 months after stopping study medications:

    • Male or female condoms
    • Diaphragm or cervical cap (with spermicide, if available)
    • Intrauterine device (IUD) or intrauterine system (IUS)
    • Hormone-based birth control (e.g., oral contraceptives, Depo-Provera, NuvaRing, implants)

    Female study candidates who are of reproductive potential, but who abstain from sexual activity that could lead to pregnancy require no additional contraception.

    Female study candidates who are not of reproductive potential are eligible without requiring the use of contraceptives. Self-reported history is acceptable documentation of menopause (i.e., at least 1 year amenorrheic), hysterectomy, bilateral oophorectomy, or bilateral tubal ligation; these candidates are all considered not of reproductive potential.

  9. For male study candidates who engage in sexual activity that may lead to pregnancy in their partner must agree to either remain abstinent or use male contraceptives. They are also strongly advised to inform their non-pregnant sexual partners of reproductive potential to use effective contraceptives while the individual is on study and for 90 days after experimental treatment discontinuation.

    For male study candidates who have undergone successful vasectomy with documented azoospermia or have documented azoospermia for any other reason, are eligible without requiring the use of contraceptives.

  10. For male study candidates with pregnant partners, willingness to use condoms during vaginal intercourse while on study and for 90 days after experimental treatment discontinuation.

  11. For male study candidates, willingness to refrain from sperm donation while on study and for 90 days after experimental treatment discontinuation.

  12. Documentation of Karnofsky performance score ≥60 obtained within 14 days prior to study entry.

  13. Chest x-ray obtained within 14 days prior to study entry.

  14. A verifiable address or residence readily accessible for visiting, and willingness to inform the study team of any change of address during study treatment and follow-up period.

  15. Ability and willingness of individual to provide informed consent.

Exclusion Criteria:

  1. More than cumulative 7 days of treatment directed against active TB for the current TB episode in the 60 days preceding study entry.
  2. Current extrapulmonary TB, in the opinion of the investigator.
  3. QTcF interval >450 ms within 7 days prior to study entry.
  4. History of or ongoing heart failure.
  5. Personal or family history of congenital QT prolongation.
  6. History of known, untreated, ongoing hypothyroidism.
  7. History of or ongoing bradyarrhythmia.
  8. History of torsades de pointes.
  9. Current Grade 2 or higher peripheral neuropathy.
  10. Other medical conditions (e.g., diabetes, liver or kidney disease, blood disorders, chronic diarrhea), in the opinion of the site investigator, in which the current clinical condition of the participant is likely to prejudice the response to, or assessment of, treatment.
  11. Pregnant or breastfeeding or planning to become pregnant within the next 12 months.
  12. Weight <35 kg.
  13. Unable to take oral medications.
  14. Taking any of prohibited medications.
  15. Known allergy/sensitivity or any hypersensitivity to components of investigational agents or their formulation.
  16. Active drug or alcohol use or dependence; or mental illness (e.g., major depression) that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  17. Taking an investigational drug or vaccine within 30 or more days prior to study entry.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Arm 1: Standard of Care (SOC)
  • Weeks 1-8: INH 300 mg, RIF 600 mg, PZA weight-based, EMB weight-based
  • Weeks 9-26: INH 300 mg, RIF 600 mg (or weight-based dosing following WHO guidance)

INH 300 mg will be administered as one tablet orally once daily.

他の名前:
  • INH

RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.

他の名前:
  • RIF

PZA will be administered as 500 mg tablets, based on weight, orally once daily.

他の名前:
  • PZA

EMB will be administered as 400 mg tablets, based on weight, orally once daily.

他の名前:
  • EMB
実験的:Arm 2: Bedaquiline (BDQ), Pretomanid (Pa), and Linezolid (LZD)
  • Weeks 1-8: BDQ 400 mg for 2 weeks and then 200 mg for 6 weeks, Pa 200 mg, LZD 600 mg
  • Weeks 9-26: INH 300 mg, RIF 600 mg (or weight-based dosing following WHO guidance)

INH 300 mg will be administered as one tablet orally once daily.

他の名前:
  • INH

RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.

他の名前:
  • RIF

BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.

他の名前:
  • BDQ

Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.

他の名前:
  • パ

LZD 600 mg will be administered as one 600 mg tablet orally once daily.

他の名前:
  • LZD
実験的:Arm 3A: BDQ, Pa and TBI-223 (1200 mg)
  • Weeks 1-8: BDQ 400 mg for 2 weeks and then 200 mg for 6 weeks, Pa 200 mg, TBI-223 1200 mg
  • Weeks 9-26: INH 300 mg, RIF 600 mg (or weight-based dosing following WHO guidance)

INH 300 mg will be administered as one tablet orally once daily.

他の名前:
  • INH

RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.

他の名前:
  • RIF

BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.

他の名前:
  • BDQ

Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.

他の名前:
  • パ

TBI-223 2400 mg once daily will be administered as four 600 mg tablets orally once daily with a meal.

TBI-223 1200 mg once daily will be administered as two 600 mg tablets orally with a meal.

実験的:Arm 3B: BDQ, Pa and TBI-223 (2400 mg)
  • Weeks 1-8: BDQ 400 mg for 2 weeks and then 200 mg for 6 weeks, Pa 200 mg, TBI-223 2400 mg
  • Weeks 9-26: INH 300 mg, RIF 600 mg (or weight-based dosing following WHO guidance)

INH 300 mg will be administered as one tablet orally once daily.

他の名前:
  • INH

RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.

他の名前:
  • RIF

BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.

他の名前:
  • BDQ

Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.

他の名前:
  • パ

TBI-223 2400 mg once daily will be administered as four 600 mg tablets orally once daily with a meal.

TBI-223 1200 mg once daily will be administered as two 600 mg tablets orally with a meal.

実験的:Arm 4A: BDQ, Pa and Sutezolid (SZD) (800 mg)
  • Weeks 1-8: BDQ 400 mg for 2 weeks and then 200 mg for 6 weeks, Pa 200 mg, SZD 800 mg
  • Weeks 9-26: INH 300 mg, RIF 600 mg (or weight-based dosing following WHO guidance)

INH 300 mg will be administered as one tablet orally once daily.

他の名前:
  • INH

RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.

他の名前:
  • RIF

BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.

他の名前:
  • BDQ

Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.

他の名前:
  • パ

SZD 1600 mg once daily will be administered as four 400 mg tablets orally once daily with a meal.

他の名前:
  • SZD

SZD 800 mg once daily will be administered as two 400 mg tablets orally once daily with a meal.

他の名前:
  • SZD
実験的:Arm 4B: BDQ, Pa and SZD (1600 mg)
  • Weeks 1-8: BDQ 400 mg for 2 weeks and then 200 mg for 6 weeks, Pa 200 mg, SZD 1600 mg
  • Weeks 9-26: INH 300 mg, RIF 600 mg (or weight-based dosing following WHO guidance)

INH 300 mg will be administered as one tablet orally once daily.

他の名前:
  • INH

RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.

他の名前:
  • RIF

BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.

他の名前:
  • BDQ

Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.

他の名前:
  • パ

SZD 1600 mg once daily will be administered as four 400 mg tablets orally once daily with a meal.

他の名前:
  • SZD

SZD 800 mg once daily will be administered as two 400 mg tablets orally once daily with a meal.

他の名前:
  • SZD

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Difference in mean log10 (Time to positivity (TTP)) slope from longitudinal mycobacteria growth indicator tube (MGIT) liquid culture measurements over the first 6 weeks of treatment
時間枠:Weeks 0, 1, 2, 3, 4 and 6

for each experimental treatment arm compared to the SOC treatment arm.

Weeks 0, 1, 2, 3, 4 and 6
Difference in the cumulative proportion of participants having at least one new Grade 3 or higher adverse event (AE) by week 8 of treatment
時間枠:8 weeks

for each experimental treatment arm compared to the SOC treatment arm.

8 weeks

二次結果の測定

結果測定
時間枠
2回の連続測定におけるMGIT液体培養による培養陰性ステータスによって測定された、8週目までに安定した喀痰培養変換を示した参加者の累積割合。
時間枠:8週間
8週間
治療の最初の 8 週間にわたる縦方向の MGIT 液体培養測定からの平均 log10 TTP 勾配。
時間枠:0、1、2、3、4、6、8週目
0、1、2、3、4、6、8週目
治療26週目までに新たにグレード3以上のAEを発症した参加者の累積割合。
時間枠:26週間
26週間
治療8週間前に何らかの理由で研究で提供された抗結核薬を永久に中止した参加者の累積割合。
時間枠:8週間
8週間
治療8週間前に何らかの理由で少なくとも1種類の抗結核薬を永久中止または3日間以上一時中止した参加者の累積割合。
時間枠:8週間
8週間
治療開始 26 週間前に何らかの理由で少なくとも 1 種類の抗結核薬の使用を永久に中止した参加者の累積割合。
時間枠:26週間
26週間
治療6週目での安定した培養変換と8週目までの新たなグレード3以上のAEの複合。
時間枠:8週間
8週間
治療開始後52週間までに持続的に治癒した参加者の割合。
時間枠:52週間
52週間

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

協力者

捜査官

  • スタディチェア:Radojka Savic, PharmD, PhD、University of California
  • スタディチェア:Kelly Dooley, MD, PhD、Vanderbilt University Medical Center
  • スタディチェア:Gustavo Velásquez, MD, MPH、University of California

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年3月11日

一次修了 (推定)

2027年3月1日

研究の完了 (推定)

2028年1月3日

試験登録日

最初に提出

2023年12月20日

QC基準を満たした最初の提出物

2023年12月20日

最初の投稿 (実際)

2024年1月5日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月2日

QC基準を満たした最後の更新が送信されました

2026年10月29日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Individual participant data that underlie results in the publication, after deidentification.

IPD 共有時間枠

Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.

IPD 共有アクセス基準

  • With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.
  • For what types of analyses? To achieve aims in the proposal approved by the AIDS Clinical Trials Group.
  • By what mechanism will data be made available? Researchers may submit a request for access to data using the AIDS Clinical Trials Group "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する